Codexis, Inc. (NASDAQ:CDXS), a developer of industrial enzymes to enable the cost-advantaged production of biofuels, bio-based chemicals and pharmaceutical intermediates, today announced that Brian Dowd has resigned as interim Chief Financial Officer, Vice President and Controller, effective June 28, 2012, in order to accept a position at a private technology company. John J. Nicols, the company’s newly appointed President and Chief Executive Officer, and the Board of Directors will continue Codexis’ ongoing search for a permanent CFO.
“We thank Brian for his contributions to Codexis,” said Mr. Nicols. “We are grateful for his leadership, and we all wish Brian the best in his new position.”
About Codexis, Inc.
Codexis, Inc. is a developer of industrial enzymes to enable the cost-advantaged production of biofuels, bio-based chemicals and pharmaceutical intermediates. Codexis' product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol. Partners and customers include global leaders such as Shell, Merck and Pfizer. For more information, see www.codexis.com.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts